Thyroid disorders induced by immune checkpoint inhibitors therapy of malignant tumors

Author:

Glibka Anastasiya A.ORCID,Mazurina Natalya V.ORCID,Sarantseva Ksenia A.ORCID,Kharkevich Galina Y.ORCID,Laktionov Konstantin K.ORCID,Troshina Ekaterina A.ORCID,Mel`nichenko Galina A.ORCID

Abstract

In the recent years, immune checkpoint inhibitors (ICPI) have been widely used for treatment of many malignant neoplasms. In the Russian Federation, several ICPIs have been approved and actively used, namely anti-CTLA-4 monoclonal antibody (ipilimumab), anti-PD-1 monoclonal antibodies (nivolumab, pembrolizumab, prolgolimab), and anti-PD-L1 monoclonal antibodies (atezolizumab, durvalumab). ICPIs may cause various endocrine immune-mediated adverse events, most commonly thyroid dysfunction and hypophysitis, which are at large associated with anti-tumor therapy with a certain subgroup of these agents. Predictors of endocrine immune-mediated adverse events remain unclear, and their optimal prevention, prediction and treatment have not been yet defined. The review contains the information accumulated in the literature on the mechanisms, biomarkers, specific characteristics of thyroid immune-mediated adverse events and describes the principles of treatment for these thyroid disorders. This information would be useful for practicing oncologists, endocrinologists, internists, family physicians, as well as for any other medical specialties.

Publisher

Moscow Regional Research and Clinical Institute (MONIKI)

Subject

General Earth and Planetary Sciences,General Environmental Science

Reference33 articles.

1. Institute for Health Metrics and Evaluation (IHME). Global Burden of Disease Study 2019 (GBD 2019) Cause List Mapped to ICD Codes [Internet]. Mar 12, 2022. Available from: https://ghdx.healthdata.org/record/ihme-data/gbd-2019-cause-icd-code-mappings.

2. Diagnosis and treatment of endocrinological complications of immunotherapy of oncological diseases

3. Immuno-related endocrinopathy in patients treated with immune checkpoint inhibitors

4. Low frequency of positive antithyroid antibodies is observed in patients with thyroid dysfunction related to immune check point inhibitors

5. Thyroid disorders induced by checkpoint inhibitors

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3